Correction: Applying Clinical Trial Evidence for Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema to Clinical Practice

Category	Detail
Condition	Correction notice for an article about applying clinical trial evidence for aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema.
Key Mechanisms	Not described in the correction notice.
Target Population	Not specified in the correction notice.
Care Setting	Not specified in the correction notice.

Typos in the text, references, funding statement, and competing interest section were corrected.
The original article has undergone correction.
The correction was published online on 07 August 2026.

The correction notice does not provide patient eligibility or population details.

The article concerns aflibercept 8 mg, but the correction notice provides no dosing, efficacy, safety, or prescribing details.

Clinical Scorecard: Correction: Applying Clinical Trial Evidence for Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema to Clinical Practice